University of Montana

ScholarWorks at University of Montana
Biomedical and Pharmaceutical Sciences Faculty
Publications

Biomedical and Pharmaceutical Sciences

1997

Multiple Ionic Conductances of the Human
Dopamine Transporter: The Actions of Dopamine
and Psychostimulants
Mark S. Sonders
Si-Jia Zhu
Nancy R. Zahniser
Michael Kavanaugh
University of Montana - Missoula

Susan G. Amara

Let us know how access to this document benefits you.
Follow this and additional works at: https://scholarworks.umt.edu/biopharm_pubs
Part of the Medical Sciences Commons, and the Pharmacy and Pharmaceutical Sciences
Commons
Recommended Citation
Sonders, Mark S.; Zhu, Si-Jia; Zahniser, Nancy R.; Kavanaugh, Michael; and Amara, Susan G., "Multiple Ionic Conductances of the
Human Dopamine Transporter: The Actions of Dopamine and Psychostimulants" (1997). Biomedical and Pharmaceutical Sciences
Faculty Publications. 56.
https://scholarworks.umt.edu/biopharm_pubs/56

This Article is brought to you for free and open access by the Biomedical and Pharmaceutical Sciences at ScholarWorks at University of Montana. It has
been accepted for inclusion in Biomedical and Pharmaceutical Sciences Faculty Publications by an authorized administrator of ScholarWorks at
University of Montana. For more information, please contact scholarworks@mso.umt.edu.

The Journal of Neuroscience, February 1, 1997, 17(3):960 –974
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1

Electrophysiological and pharmacological studies of a cloned
human dopamine transporter (hDAT) were undertaken to investigate the mechanisms of transporter function and the actions
of drugs at this target. Using two-electrode voltage-clamp
techniques with hDAT-expressing Xenopus laevis oocytes, we
show that hDAT can be considered electrogenic by two criteria.
(1) Uptake of hDAT substrates gives rise to a pharmacologically
appropriate “transport-associated” current. (2) The velocity of
DA uptake measured in oocytes clamped at various membrane
potentials was voltage-dependent, increasing with hyperpolarization. Concurrent measurement of transport-associated current and substrate flux in individual oocytes revealed that
charge movement during substrate translocation was greater
than would be expected for a transport mechanism with fixed
stoichiometry of 2 Na1 and 1 Cl2 per DA1 molecule. In addition
to the transport-associated current, hDAT also mediates a
constitutive leak current, the voltage and ionic dependencies of

which differ markedly from those of the transport-associated
current. Ion substitution experiments suggest that alkali cations
and protons are carried by the hDAT leak conductance. In
contrast to the transport-associated functions, the leak does
not require Na1 or Cl2, and DAT ligands readily interact with
the transporter even in the absence of these ions. The currents
that hDAT mediates provide a functional assay that readily
distinguishes the modes of action of amphetamine-like “DAreleasing” drugs from cocaine-like translocation blockers. In
addition, the voltage dependence of DA uptake suggests a
mechanism through which presynaptic DA autoreceptor activation may accelerate the termination of dopaminergic neurotransmission in vivo.

The dopamine transporter (DAT) is thought to be a principal site
of action for several psychomotor stimulants, including cocaine,
amphetamine, methamphetamine, and methylphenidate— drugs
used widely for both therapeutic and nontherapeutic purposes.
After release of the neurotransmitter dopamine (DA), its extracellular concentrations are regulated primarily by reaccumulation
into dopaminergic neurons through the action of DAT and by
diffusion. Accordingly, pharmacological inhibition of DA uptake
may both prolong the duration of DA action at its receptors and
expand the spatial domain of its actions in a manner comparable
to that reported for GABA uptake inhibition (Isaacson et al.,
1993). Numerous in vivo microdialysis and electrochemical studies
have shown that psychomotor stimulants raise extracellular DA
concentrations (for review, see Wise, 1996). Similarly, in vitro and
in vivo electrophysiological experiments demonstrate that stimulant actions are consistent with elevation of DA concentrations
(for review, see Lacey, 1993; White, 1996). Although cocaine,
amphetamine, and many of their congeners display comparable
actions at serotonin and norepinephrine transporters (SERT and
NET), DAT is the pharmacological target best correlated with

their reinforcing properties and abuse potential (Ritz et al., 1987;
Nestler et al., 1993; Pulvirenti and Koob, 1994; Wise, 1996). Gene
disruption experiments demonstrate that DAT may be the principal mediator of the locomotor stimulatory effects of cocaine and
amphetamine, and that DAT plays a critical role setting dopaminergic “tone” in the murine CNS (Giros et al., 1996). Thus, there
is considerable interest in understanding the molecular mechanisms by which DAT functions.
DAT belongs to a recently cloned family of neurotransmitter
and amino acid transporters that are functionally related by their
requirement for extracellular Na1 and Cl2 (Amara and Kuhar,
1993). These transporters operate by coupling the transmembrane
translocation of organic substrates to the movement of driving
ions down preestablished electrochemical gradients (Kanner and
Schuldiner, 1987; Rudnick and Clark, 1993). Biochemical studies
of the dependence of DA uptake on Na1 and Cl2 concentrations
suggest that two Na1 ions and one Cl2 ion are cotransported with
each DA molecule (Krueger, 1990; McElvain and Schenk, 1992;
Kilty, 1993; Gu et al., 1994). These results predict that the transport of each DA1 molecule will be accompanied by the movement
of two net positive charges (because DA is positively charged at
physiological pH), and will thereby generate an inward current.
A number of neurotransmitter/ion cotransporters generate detectable electrical currents during the process of substrate translocation both in situ and in reconstituted systems. Certain transporters, furthermore, exhibit ion channel-like electrical activities
that would not be predicted from classical alternating-access models of carrier function (for review, see Lester et al., 1994; DeFelice
and Blakely, 1996; Sonders and Amara, 1996). To investigate the
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electrogenic properties of DAT, we have studied a cloned human
DAT with two-electrode voltage-clamp methods. By expressing
hDAT in Xenopus laevis oocytes and applying a combination of
electrophysiological, pharmacological, and biochemical techniques, we can assess its translocation activity in real time and
examine in greater detail the voltage dependence, ionic coupling,
and channel-like properties of this carrier. These studies also
provide insights into the actions of an important class of neuropharmacological agents.

MATERIALS AND METHODS
hDAT cloning and expression. Total RNA was extracted according to the
method of Chomczynski and Sacchi (1987) from a single human midbrain
sample and reverse-transcribed into cDNA using SuperScript II (Life
Technologies, Grand Island, NY) and the oligonucleotide GTCTTCGTCTCTGCTCCC complementary to the sense strand of hDAT
subsequent to the termination codon (Giros et al., 1992; Vandenbergh et
al., 1992). hDAT cDNA was amplified by PCR using Vent DNA polymerase (New England Biolabs, Beverly, MA) and primers overlapping 23
and 21 nucleotides of the 59 and 39 ends of the 1860 nucleotide coding
region. The PCR transcript was digested and directionally ligated into the
oocyte transcription vector pOTV (Arriza et al., 1994). The insert was
sequenced in its entirety and found to be identical at the nucleotide level
to the hDAT allele reported by Vandenbergh et al. (1992) (GenBank
accession no. M95167). Capped cRNA was transcribed from linearized
DAT plasmid using T7 polymerase (mMessage mMachine, Ambion),
diluted with water, and injected into defolliculated stage V or VI oocytes
(;10 ng/oocyte). Oocytes were prepared as described by Quick and
Lester (1994) and maintained at 17 or 218C for up to 3 weeks. The
presence of hDAT in cRNA-injected oocytes was confirmed by Western
blot analyses, which displayed immunoreactive bands not detected in
water-injected oocytes.
Uptake assays. Transport of DA into individual oocytes was quantitated
either by liquid scintillation spectroscopy of [3H]DA or HPLC-coupled
electrochemical detection (HPLC-EC) of nonradiolabeled DA. All uptake experiments were performed at ambient temperature using frog
Ringer’s solution, containing (in mM): 96 NaCl, 2 KCl, 1.8 CaCl2, 1
MgCl2, and 5 HEPES-NaOH, pH 7.4 –7.5, or ion-substituted versions, as
specified. Uptake kinetic experiments were initiated with the addition of
tritiated or unlabeled DA to groups of oocytes (3– 6) in a final volume of
500 ml and terminated by transferring the oocytes through three sequential 5 ml baths of ice-cold Ringer’s (total transfer time, ,20 sec). Radiolabeled DA was quantitated by liquid scintillation spectroscopy after
dissolving individual oocytes in 250 ml of 0.2% SDS. Intracellular DA
concentration determination by HPLC-EC (Gerhardt et al., 1989) was
performed by sonicating individual oocytes in 0.8 ml of 2 mM perchloric
acid and chromatographing aliquots equivalent to 1/50-1/160 of the
centrifugation supernatant (16,000 3 g, 48C, 15 min). Retention time of
standards was used to identify peaks, and peak heights were used to
calculate absolute amounts of DA. Nominal detection limits for DA and
dihydroxyphenylacetic acid were 0.5 and 0.25 pg per injection,
respectively.
The velocity of DA uptake was essentially constant over incubation
periods between 0.5 and 60 min using 75–200 nM [3H]DA. Accordingly,
incubation periods between 100 sec and 30 min were used in uptake
studies. Saturation experiments used at least eight DA concentrations
between 10 nM and 1 mM. Nonspecific uptake was determined by performing parallel incubations of water-injected oocytes or of cRNAinjected oocytes in the presence of saturating concentrations of uptake
inhibitors mazindol, cocaine, RTI-55, or GBR 12909. Nonspecific uptake
of radioligand was always ,3% of total uptake, and for incubations $5
min, it was typically ,1% of total uptake. Oocytes were preincubated in
drug/buffer solutions for at least 5 min before addition of [3H]DA.
In ion substitution experiments, Na1 or Cl2 ions in frog Ringer’s
solution were either partially or fully replaced. LiCl and KCl were used to
replace NaCl, and in most cases, LiOH and KOH were used to adjust the
pH of the buffers. Cl2 substitution experiments were performed with
morpholinoethylsulfonate (MES)-NaOH and MES-LiOH in place of
NaCl at a concentration of 96 mM, either with 6.6 or 0 mM Cl2 remaining.
In the latter case, KNO3, Ca(NO3)2, and MgSO4 were used in place of the
corresponding chloride salts.
For uptake and binding data, nonlinear regression analyses were performed with KaleidaGraph 3.0 or GraphPAD software to generate esti-
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mates of kinetic constants KT (the apparent affinity of transport), Vmax, Ki,
IC50, KD, and Bmax. Ki values were calculated from IC50 using the
Cheng–Prusoff equation. Geometric means were determined for the
apparent affinity values KT, Ki, KD, and IC50. Error values are given as
SEMs or, where appropriate, 95 or 99% confidence intervals (CI95
or CI99).
Drugs were obtained from National Institute on Drug Abuse Research
Technology Branch or were purchased from Research Biochemicals
International (Natick, MA) or Sigma (St. Louis, MO). Radiochemicals
were purchased from DuPont NEN (Boston, MA) and Amersham (Arlington Heights, IL).
Determination of hDAT density and turnover rate. The turnover rate of
hDAT was estimated from the ratio Vmax:Bmax. In each of three batches
of oocytes, parallel measurements were made of the velocity of DA
uptake (Vmax) and the density of hDAT sites (Bmax). Vmax values were
calculated from saturation analyses of assays using either liquid scintillation spectrometry or HPLC-EC to quantitate accumulation of tritiated or
unlabeled DA, respectively (8 concentrations, triplicate determinations).
Saturation binding assays were performed on intact ooctyes using 5 nM
[3H]mazindol and six concentrations of unlabeled mazindol (1 nM–1 mM,
triplicate determinations) in frog Ringer’s solution. Oocytes were incubated in 1 ml of [3H]mazindol solutions for 45– 60 min on ice, washed for
5–10 sec in 4 ml of ice-cold buffer, and then solubilized individually in 200
ml of 1% SDS. Radioactivity was determined with liquid scintillation
counting. Nonspecific binding was determined with 1 mM GBR 12909.
Two-electrode voltage-clamp electrophysiology. Two-microelectrode
voltage-clamp recordings from oocytes were performed at room temperature using glass microelectrodes filled with 3 M KCl solutions (resistance,
,1 MV) and an Ag/AgCl-pellet bath ground or an active bath probe.
Dagan TV-200, Axon GeneClamp 500, or Warner OC-725B amplifiers
were used with AxoLab-1 or DigiData1200 interfaces. The pClamp suite
of programs (Axon Instruments, Foster City, CA) was used to control
stimulation parameters, for data acquisition, and for analysis. MacLab
data acquisition software and a MacLab/2e interface (ADInstruments,
Milford, MA) were used simultaneously to monitor and record electrophysiological experiments. Currents were low-pass filtered between 10 Hz
and 2 kHz, and digitized at rates between 1 and 5 kHz. Frog Ringer’s
buffer and ion-substituted versions (described above) were superfused
over voltage-clamped oocytes at a rate of ;4 ml/min (bath volume, 0.5
ml). During Cl2 substitution experiments, 3 M KCl/agar bridges were
used to avoid voltage offsets associated with buffer changes.
The voltage dependence of hDAT-mediated currents was studied using
two voltage excursion protocols. In one protocol, membrane potentials
were ramped between 2130 mV and 180 mV over a 750 msec interval.
The second protocol used a sequence of jumps in membrane potential in
10 mV increments to measure steady-state currents at potentials between
2120 mV and 140 mV. Oocytes were held at 260 mV (600 –750 msec)
before jumps to each test potential (duration 250 – 400 msec). Before
each application of drug, two voltage excursions were executed to measure the control currents and establish that they were stable. For voltage
jump protocols, current values were measured and averaged during the
final 80 msec of the test interval when they had reached steady state.
Currents attributable to the actions of drugs were determined by
performing off-line subtraction of currents recorded during buffer perfusion (control) and currents recorded during drug perfusion. Substrateelicited currents were measured by subtracting the control currents from
those recorded during substrate application (IDrug 2 IControl). However,
changes in membrane current brought about by nonsubstrate transport
antagonists were determined by a subtraction using a reversed order
(IControl 2 IDrug), because these drugs appear only to block membrane
conductances. This convention is obeyed in all figures except Figure 3, in
which the aim is to compare the actions of DA and cocaine, and all data
are plotted as IDrug 2 IControl. The sole exception to the pattern of
DA-elicited currents being plotted as IDA 2 IControl is found in Figure 7:
under Na1-free conditions, all DAT ligands only block a membrane
conductance; hence, the current–voltage (I–V ) of the conductances
blocked by DA and cocaine are both plotted as IControl 2 IDrug.
Concentration–response data were collected by measuring subtracted currents (IDA 2 IControl) during voltage jump protocols. To six
oocytes, concentrations of DA were superfused at least twice (in
randomized order), and the two responses for each concentration were
averaged. The concentrations studied were 0.1, 0.3, 1.0, 3.0, 10.0, and
30.0 mM, although the 30 mM concentration was examined in only five
oocytes. To control for variation in expression levels between oocytes,
the concentration dependence and voltage dependence of DA-evoked
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currents were analyzed by normalizing current responses in an individual oocyte to that evoked by 10 mM DA at 2120 mV. The DA
concentrations evoking a half-maximal current (K0.5) at single membrane potentials were determined by nonlinear regression using the
Michaelis–Menten equation. At potentials greater than 220 mV, responses evoked by 30 mM DA were omitted from the regressions
because at high concentrations, several phenethylamines appeared to
block endogenous channels. The voltage dependence of mean normalized currents evoked at each DA concentration was studied by nonlinear regression analysis. Comparable experiments were performed using
S(1)amphetamine over the concentration range 0.03–30 mM.
DA uptake under voltage-clamp conditions. The dependence of DA
uptake velocity on membrane potential was studied by measuring substrate accumulation in oocytes held in voltage-clamp at various potentials
(110, 0, 230, 260, 290, or 2120 mV). DA uptake was measured in six
batches of oocytes either by HPLC-EC after 3 or 5 min perfusions of 20
mM DA, or by liquid scintillation spectroscopy after 100 sec perfusions
with 10.1 mM [3H]DA (0.37 Ci/mmol). After incubations with DA or
[3H]DA, oocytes were briefly superfused with frog Ringer’s, voltage
clamps were shut off, electrodes were withdrawn, and the oocytes were
transferred to either perchlorate or SDS solutions and treated as described above (#30 sec). DA uptake velocities were calculated on a
per-second basis. The voltage dependence of uptake velocity was quantified in each batch of oocytes by normalizing mean velocities at each
potential to that measured at 230 mV. Net charge movement attributable
to substrate translocation during DA/[3H]DA perfusion was calculated
off-line by graphically integrating the DA-elicited current in each oocyte
with MacLab (5 of 6 oocyte batches). For each oocyte, an estimate of the
net charge:DA flux ratio was calculated as follows: Net Charges Translocated/(Moles of Accumulated DA 3 Faraday Constant).
Ion substitution experiments. Reversal potentials were determined by
visual inspection of I–V plots generated with Clampfit. After each cocaine
perfusion, oocytes were perfused for at least 8 min before subsequent
drug applications to allow adequate drug washout. Ion permeability ratios
were calculated from shifts in the reversal potential of cocaine-elicited
currents in different ion-substituted buffers using the Goldman–Hodgkin–
Katz voltage equation (Hille, 1992).

RESULTS
DA uptake studies
To establish the validity of the Xenopus oocyte expression system
for investigating the electrophysiological properties of hDAT, the
kinetic and pharmacological properties of [3H]DA uptake were
studied. Levels of hDAT expression were fairly consistent among
oocytes of a single injection batch; however, they varied widely
between batches of oocytes. The time of maximal hDAT expression also varied between batches, peaking between 4 and 14 d
after injection. Oocytes expressing hDAT accumulated [3H]DA in
a time- and ion-dependent manner. For instance, when oocytes
from four separate batches were incubated in [3H]DA (30 –150
nM) for 30 min, they accumulated radioligand to levels .40-fold
above external concentrations, assuming an intracellular aqueous
volume of 0.5 ml (n 5 12 assays). By contrast, control oocytes from
these and other batches did not concentrate [3H]DA whatsoever,
and excluded more than three-fourths the radioactivity found in a
comparable volume of incubation bath (n . 60 assays). Control
oocytes included uninjected and water-injected oocytes, or cRNAinjected oocytes that were coincubated with $3 mM mazindol, $20
mM cocaine, $1 mM RTI-55, or 1 mM GBR 12909. [3H]DA uptake
displayed strong Na1 and Cl2 dependence: complete replacement of Na1 with Li1, K1, Cs1, or choline reduced [3H]DA
uptake by 97–98% (n $ 2 assays for each substitute). Complete
replacement of external Cl2 diminished [3H]DA uptake by
96.5%; in comparison, parallel water-injected oocytes accumulated 98.9% less than hDAT cRNA-injected oocytes (n 5 2
assays).
Kinetic parameters for DA translocation by hDAT were similar
in uptake assays using either liquid scintillation spectroscopy to

Table 1. hDAT turnover rate determined from saturation analyses of
DA uptake velocity and [3H]mazindol binding to intact oocytes
DA uptakea
Vmax
(fmol /(oocyte 3 sec))
66.9 6 6.3

KT
(mM)
2.7b

[3H]mazindol binding

Turnover rate

Bmax
(fmol /oocyte)
152.5 6 7.0

Vmax /Bmax
(sec21)
0.47 6 0.06

KD
(nM)
5.2 c

Mean values (6SEM) for Vmax and Bmax were determined in three experiments using
different oocyte batches (not voltage-clamped). In each experiment, parallel pools of
oocytes were used for Vmax and for Bmax measurements.
a
DA uptake was measured solely with [3H]DA in one experiment and solely by
HPLC-EC in a second experiment. Both methods were used in a third experiment
and yielded Vmax values that differed by 7%.
b
CI95 0.2–36 mM.
c
CI95 2.9 –9.2 nM.

detect accumulated [3H]DA or HPLC-EC to measure intracellular DA. Saturation uptake experiments performed at 218C with six
different oocyte batches yielded a mean KT value of 1.7 mM (CI95
0.7– 4.1 mM). Greater batch-to-batch variability was observed in
DA uptake velocity than in apparent affinity, as would be expected
to result from differing levels of hDAT expression. (Vmax values
ranged between approximately 15 and 400 fmol /sec (218C) over
all experiments.) Cocaine and S(1)amphetamine inhibited uptake of [3H]DA in a concentration-dependent manner with mean
Ki values of 206 nM (CI95 102– 414 nM; n 5 3) and 297 nM (CI95
137– 647 nM; n 5 3), respectively. Cocaine exhibited a Schild slope
(Kenakin, 1987) of 0.94 (1 experiment), which is compatible with
a competitive interaction with DA at hDAT.

Estimation of hDAT turnover rate
To determine the turnover rate of hDAT, parallel measurements
of DA uptake velocity and hDAT density were made in three
oocyte batches to calculate the Vmax:Bmax ratio (Table 1). Maximal DA uptake velocities were measured at room temperature
using radiolabeled flux or HPLC-EC. Catabolism of accumulated
DA to dihydroxyphenylacetic acid in hDAT oocytes was not
detected by HPLC-EC analysis, indicating that accumulated tritium likely represents authentic [3H]DA. Endogenous DA was
not detected by HPLC-EC in uninjected or water-injected oocytes. The Bmax of [3H]mazindol, which labels DAT in rat striatum
with nanomolar affinity (Javitch et al., 1984), was determined on
intact oocytes to estimate the number of transporters expressed
per oocyte. A single class of binding sites with an affinity similar to
that in rat brain was revealed. Assuming that each mazindol
binding site represents a functional DAT molecule on the oocyte
surface, the mean Vmax:Bmax ratio estimates the turnover rate to
be 0.47 DA molecules /(sec 3 transporter molecule), suggesting
that each transport cycle requires ;2 sec at 218C.

Two-electrode voltage-clamp studies of hDAT currents
Preliminary calculations based on the Vmax of DA uptake by
hDAT-expressing oocytes indicated that if DA translocation were
accompanied by a net charge movement, then an inward current
attributable to hDAT transport activity should be detectable by
two-electrode voltage-clamp methods. Figure 1 A shows the
changes in membrane current elicited by drug application to a
hDAT-expressing oocyte voltage-clamped at 260 mV. Superfusion with 20 mM DA evoked a downward displacement in the
current trace, consistent with a net inward current that occurs as
a result of translocation of DA1 and Na1 ions. In contrast, 10 mM
cocaine evoked outward currents (that only slowly washed out)
both on initial application and on reapplication after DA super-
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Figure 1. Cocaine and DA applications to a voltage-clamped hDAT
oocyte evoke opposite changes in membrane current. Drug applications
(solid bars) to oocytes voltage-clamped at 260 mV. A, An hDATexpressing oocyte was initially superfused with 10 mM cocaine (Coc), which
elicited a small outward current that slowly returned to baseline after 10
min of washout (flow rate 4 ml /min, chamber volume 0.5 ml). Superfusion
of 20 mM DA induced an inward current that rapidly returned to baseline.
Reapplication of cocaine caused an outward current comparable in magnitude and kinetics to that evoked by its initial application. B, No responses were evoked by drug application to a water-injected control
oocyte.

fusion of the same oocyte. The drug-elicited currents are attributable to hDAT because they were not observed in uninjected or
water-injected oocytes (Fig. 1 B).
That cocaine could elicit any change in the holding current of
an hDAT-expressing oocyte in the absence of DA was somewhat
unexpected, because cocaine is generally viewed as a nontransported uptake inhibitor that interacts with DA in an apparently
competitive manner. It was also intriguing that the cocaineevoked current was opposite in polarity to the DA-elicited current. Even though cocaine has occasionally been reported to cause
DA release (Baumann and Maitre, 1976; Pifl et al., 1995), the
outward current elicited by cocaine does not arise from DA
extrusion because the outward current could be evoked by cocaine
before the initial presentation of extracellular DA (Fig. 1 A), and
oocytes were found by HPLC-EC to have little or no endogenous
DA (#50 nM, data not shown). The opposite DA- and cocaineelicited currents suggest that hDAT mediates at least two distinct
steady-state ionic conductances, one of which is associated with
substrate transport, whereas the other can be observed in the
absence of translocation activity. Mager and colleagues (1994)
noted analogous currents manifested by rat SERT and termed
them transport-associated and leak currents. The following experiments illustrate that the steady-state ionic conductances that give
rise to the hDAT transport-associated and leak currents are
distinguishable based on voltage dependence, ionic selectivity,
and mode of drug action.

I–V relations of transport-associated and leak currents
To better understand the changes in ionic conductance that underlie the currents mediated by hDAT, drug-evoked currents were
studied across a voltage range, using both ramp and jump protocols to control membrane potentials. The actions of drugs in
changing membrane conductance were identified by comparing
membrane currents measured during drug superfusion and during
buffer superfusion (control conditions). Subtraction of currents
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measured in the presence and absence of hDAT ligands yielded
I–V plots for the drugs.
Figure 2 shows results from a voltage ramp experiment in which
DA and cocaine were applied sequentially to a single oocyte. At
both negative and positive potentials, 3 mM cocaine superfusion
diminished the magnitude of the membrane current compared
with that measured during the control voltage ramp. This result is
consistent with the cocaine-evoked outward current observed in
an oocyte clamped at 260 mV (Fig. 1 A) and suggests that the
cocaine-elicited outward current likely reflects the action of the
drug in blocking a constitutive membrane conductance, rather
than an ability to activate either K1 ion efflux or Cl2 ion influx.
This point is made more obvious by inspection of the difference
between cocaine and control voltage ramps.
The I–V curve describing the tonic leak conductance that is
susceptible to blockade by cocaine is derived according to convention by taking the difference of IControl 2 ICocaine (Fig. 2 B).
This current was voltage-dependent, outwardly rectifying, and
reversed at approximately 210 mV. The slope and reversal potential of this current both argue against an action of cocaine to
increase membrane permeability to K1 or Cl2 ions because: (1)
the amplitude of currents carried by either ion would be expected
to increase with depolarization between 260 mV and 210 mV,
whereas the observed current decreases over this range; and (2)
the reversal potential of approximately 210 mV is more positive
than the Nernst potentials for K1 or Cl2 in oocytes (295 mV and
228 mV, respectively) (Dascal, 1987; Costa et al., 1989). That the
observed reversal potential is also more negative than the Nernst
potential for Na1 (61 mV) (Costa et al., 1989) suggests that the
tonic leak conductance may be nonselective for cations, an assertion that is more directly supported by ion substitution experiments presented below.
The effect of DA superfusion on hDAT oocyte membrane
conductance is more complex than that of cocaine because, at
extremes of the potential range, DA clearly evokes two opposite
effects. At positive potentials, DA acted to reduce the membrane
conductance compared with control in a manner analogous to
cocaine; in contrast, at negative potentials, DA superfusion increased the membrane conductance (Fig. 2C). Because DA is
believed to increase transport-associated ionic flux, the DAelicited current was determined by subtraction using the convention of IDA 2 IControl (Fig. 2 D). The resulting DA I–V curve
exhibited an asymmetric inverted U-shape, with a positive slope
conductance (at hyperpolarized potentials) representing the
transport-associated current and a negative slope conductance (at
depolarized potentials) representing a cocaine-like blocking action on a tonic leak conductance. As a result of the opposing
conventions used to describe DA-elicited and cocaine-inhibitable
I–V relationships, the similar inhibitory actions of the two drugs
on a tonic leak conductance are manifested as I–V plots with
negative slope conductance for DA but with positive slope conductance for cocaine over the range of positive potentials (Fig.
2 B,D). Despite this artificial disparity in plotting, the suggestion
that both drugs may block an identical leak conductance is explored further in ion substitution experiments presented below.
Over the range of negative potentials, Figures 1 and 2 suggest
that when applied separately, DA and cocaine may act on distinct
hDAT ionic conductances. However, because cocaine is a well
established inhibitor of DA translocation, it would be expected
that cocaine should be able to inhibit ionic flux (i.e., current) that
accompanies substrate transport. To test for the possibility of such
an interaction, voltage ramps were executed during superfusion
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Figure 2. Membrane conductance changes evoked by DA and cocaine. Currents measured in a single voltage-clamped oocyte during voltage ramps
(2130 to 180 mV in 750 msec). A, Membrane currents measured during buffer (- - -) and 3 mM cocaine (OO) superfusion. B, I–V plot describing current
that is blocked by cocaine, determined by subtraction of currents (IControl 2 ICocaine) plotted in A. C, Membrane currents measured during buffer (- - -)
and 20 mM DA (OO) superfusion. D, I–V of current elicited by DA, determined by subtraction of currents (IDA 2 IControl) plotted in C.

with DA and cocaine in combination. Figure 3 displays the I–V
values elicited by sequential application to a single representative
oocyte of 3 mM cocaine (;10 3 Ki), 2 mM DA (approximately KT),
and the two drugs together. (To facilitate comparison, only the
IDrug(s) 2 IControl convention was used for current subtractions.)
Coapplication of 2 mM DA and 3 mM cocaine gave rise to a
voltage-sensitive current that was not the sum of the individually
elicited currents but that virtually overlapped the cocaine I–V
trace. Comparison of the DA I–V values in the absence and
presence of cocaine makes clear that cocaine fully antagonized the
inward DA current otherwise seen at negative potentials. That the
DA-elicited current observed at negative potentials was abolished
by a near-saturating concentration of cocaine supports the contention that this current is closely associated with substrate translocation by hDAT.
From these data, it appears that the electrophysiological action
of cocaine on hDAT is limited to blocking ionic conductances—
either the tonically active leak conductance when cocaine is applied alone, or the transport-associated conductance when it is
coapplied with DA. DA, on the other hand, increases the
transport-associated conductance, yet also blocks the tonic leak

Figure 3. Antagonism of DA transport-associated current by cocaine. I–V
plots of currents elicited during consecutive applications to a single oocyte
of 3 mM cocaine (Coc; - - -), 2 mM DA (OO), and 3 mM cocaine plus 2 mM
DA (O O). Currents were measured during voltage ramps (2130 to 180
mV in 750 msec), and subtractions all used the IDrug 2 IControl convention.
Comparison of the DA I–V with the DA 1 Cocaine I–V reveals the
transport-associated component that is susceptible to blockade by cocaine.
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conductance in a cocaine-like manner. Hence, the observed substrate I–V plots likely represent the net effect of substrates acting
simultaneously on the two different hDAT conductances: at negative potentials, activation of the transport-associated conductance is the predominating effect, whereas at positive potentials,
blockade of the tonic leak conductance is most apparent.

Concentration and voltage dependence of
DA-elicited currents
To further explore the concentration, voltage, and ionic dependence of the transport and leak conductances, as well as their
pharmacological sensitivity, steady-state currents were measured
in oocytes during voltage jump protocols. Figure 4 A displays the
mean normalized responses elicited by application of varying DA
concentrations to six oocytes. To control for variations in expression levels between cells, the currents elicited in each oocyte were
normalized to that observed at 2120 mV in response to 10 mM
DA. For all DA concentrations, the I–V relations took the shape
of an inverted U, the peak of which was approximately 220 mV
and which resembled the subtracted I–V plots generated in nonsteady-state ramp protocols (Fig. 2 D). The amplitudes of DAelicited currents increased in a dose-related manner in all oocytes.
Comparable concentration-dependent responses were observed
in two oocytes treated with a range of S(1)amphetamine concentrations (data not shown).
Nonlinear curve fitting of the normalized I–V data suggested
that the two limbs of I–V plot divided at 220 mV are best
described by different functions. DA transport-associated inward
currents exhibited an exponential dependence on membrane potential, increasing with hyperpolarization approximately e-fold per
67 mV between potentials 220 mV and 2120 mV. In distinction,
at voltages more depolarized than 220 mV, DA-evoked currents
displayed a dependence on membrane potential that was better
described by a linear than by an exponential function. At neither
extreme of the range studied did current magnitudes appear to
saturate as a function of potential.
The concentration–response relations of DA-evoked currents
were studied at individual potentials. Figure 4, B and C, graphically represents the concentration dependence of normalized DAevoked currents at membrane potentials 2120 to 220 mV and
210 mV to 40 mV, respectively. For the transport-associated
currents, amplitudes appeared to saturate with increasing DA
concentration and were well described by Michaelis–Menten kinetics. The DA concentrations that elicited half-maximal currents
(K0.5) were calculated in each oocyte for every potential using the
Michaelis function. The plot of mean K0.5 versus membrane
4
Figure 4. Concentration and voltage dependence of DA-evoked steady-state
currents. Concentration-dependent current responses were measured in six
oocytes using a voltage jump protocol (see Materials and Methods). To
control for differing levels of hDAT expression between oocytes, IDA 2
IControl subtractions for each DA concentration and potential were normalized to the current elicited by 10 mM DA at 2120 mV in the same cell (mean,
217.9 nA; range, 27.9 to 243.5 nA). A, Nonlinear curve fitting of mean
current amplitudes for each DA concentration (x, 0.1 mM; f, 0.3 mM; Ç, 1.0
mM; l, 3.0 mM; µ, 10 mM; F, 30 mM). Over the potential range 2120 to 220
mV, DA-elicited currents displayed an exponential dependence on voltage
(mean, e-fold per 67 mV, solid lines; range, e-fold per 55–75 mV). At more
positive potentials, however, current amplitudes were better described as
having a linear relation to membrane potential (broken lines). B, The DA
concentration dependence of mean-normalized currents (E) was well fit by a
simple Michaelis –Menten equation for individual potentials over the range
2120 to 220 mV. Currents appeared to saturate with increasing [DA] and

displayed K0.5 values of 1.9 –2.9 mM. C, At potentials greater than 220 mV,
mean normalized current amplitudes (f) were more poorly described by
Michaelis–Menten kinetics as a function of concentration. In some oocyte
batches, high DA concentrations affected an endogenous conductance
(see Results), and therefore the 30 mM points (µ) were omitted from the
curve fits. D, At each membrane potential tested, geometric means of K0.5
and CI95 values (error bars) were determined from affinity values derived
individually for each of six oocytes (see Materials and Methods). The
apparent affinities (K0.5) of DA for eliciting transport-associated current
(F) and for blocking a leak current (f) are displayed. The K0.5 for the
transport-associated current (in the range of 2120 to 220 mV) demonstrates little voltage sensitivity. For comparison, also plotted is the DA
apparent substrate affinity (KT, OO; CI95 - - -) determined in uptake
assays using six different batches of oocytes. These oocytes were not
voltage-clamped, although other oocytes from the same batches displayed
resting membrane potentials in the range of 215 to 245 mV.
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potential (Fig. 4 D) illustrates that voltage has little influence on
the apparent affinity of DA between 2120 mV and 220 mV,
where the mean values fluctuated only between 1.9 and 2.9 mM.
These K0.5 values are in good agreement with the apparent affinity
for DA transport (KT 5 1.7 mM) determined in uptake assays
using oocytes that were not voltage-clamped (typical resting membrane potentials of hDAT oocytes were 215 to 245 mV). The
resemblance in apparent affinities of DA for uptake and for
eliciting transport-associated currents supports the assertion that
the currents are a manifestation of the translocation process. The
functional link between translocation and the transport-associated
current is reinforced by studies with S(1)amphetamine. Normalized S(1)amphetamine concentration–response curves generated
in two oocytes yielded a mean K0.5 of 0.5 mM over hyperpolarized
potentials (data not shown). This value closely corresponds to its
potency (Ki 5 0.3 mM) for inhibiting [3H]DA uptake, as would be
expected for a DA uptake inhibitor that is itself a transport
substrate (Ross, 1976).
Although the Michaelis–Menten function provided a less satisfactory fit to the DA concentration dependence of current at
voltages more positive than 220 mV (Fig. 4C), the estimates of
mean DA K0.5 values (1.0 –2.0 mM) at depolarized potentials were
in the same range as those found for hyperpolarized potentials
(Fig. 4 D) and for the KT. A number of factors may have contributed to the poorer fits of the DA currents to Michaelis–Menten
kinetics at potentials more positive than 220 mV, one of which is
that in certain batches of uninjected and water-injected oocytes,
high concentrations ($30 mM) of DA and other phenethylamine
congeners were observed to block an endogenous ionic conductance (data not shown). In particular, such a phenomenon might
account for why the largest divergences from the Michaelis–
Menten model were observed at the highest DA concentrations.
Accordingly, only concentrations up to 10 mM were used to estimate the apparent affinity of DA for blocking the leak conductance (Fig. 4C,D). Although there is some uncertainty in determining the apparent affinity of DA in blocking the leak
conductance, the results presented in Figure 4 D argue that DA
has quite comparable potencies as a transport substrate (KT), in
evoking a transport-associated current, and in blocking a leak
current (K0.5). In turn, the comparable affinities of DA for influencing the three functions support the assertion that all three are
mediated by hDAT.

Dependence of DA transport velocity on
membrane potential
The finding that DA uptake by hDAT is closely associated with an
inward current is consistent with the hypothesis that the translocation process itself is electrogenic, because it couples the movement of some net charge with DA flux, as has been proposed for
rat DAT by Krueger (1990), McElvain and Schenk (1992), Kilty
(1993), and Gu et al. (1994). If transport-associated currents arise
from a fixed stoichiometric coupling of driving ions to DA during
translocation, two corollaries should follow, i.e., that the net
charge:DA flux ratio should not vary with membrane potential,
and that DA transport velocity should increase with membrane
hyperpolarization in an exponential manner akin to the steadystate, transport-associated current (Fig. 4 A).
To examine the voltage dependence of DA uptake velocity and
the hypothesis of fixed stoichiometric coupling, the rates of DA
accumulation were quantified in individual oocytes held under
voltage clamp and superfused (#300 sec) with 20 mM DA or 10.1
mM [3H]DA. In each of six batches of oocytes, mean DA uptake
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velocity increased with membrane hyperpolarization (3– 8 oocytes /potential). Pooled results from six batches (each normalized
to its 230 mV value) are presented in Figure 5A, and these
demonstrated a clear voltage dependence of DA uptake velocity.
The mean uptake velocity in oocytes clamped at 2120 mV was
85% faster than that observed in those clamped at 230 mV.
Although uptake velocities increased with hyperpolarization in all
experiments, marked batch-to-batch differences in the magnitudes
of increase were observed. In the different batches, uptake velocities observed in oocytes held at 290 were between 12 and 108%
higher than the corresponding velocities measured at 230 mV.
Moreover, these variations did not correlate with variations in
levels of hDAT expression.

Correlation of charge and substrate fluxes
Time integrals of the DA-elicited currents were calculated for
oocytes in five of the six batches used for clamped uptake studies.
These measures of charge movement were correlated with the
quantity of DA concurrently accumulated by the same oocytes,
yielding a net charge:DA flux ratio for each of the 84 oocytes
studied. Because this ratio eliminates the effect of differing expression levels between oocytes, net charge:DA flux determinations could be pooled for all oocytes held at each membrane
potential. As Figure 5B illustrates, the charge:DA flux ratio displayed a minimum at 230 mV of 3.1 6 0.26 e0 / DA molecule
(mean 6 SEM; n 5 24), and the ratio increased with either
hyperpolarization or depolarization from that potential (260 mV,
3.8 6 0.4, n 5 26; 290 mV, 4.1 6 0.3, n 5 24; 2120 mV, 6.6 6
0.9, n 5 10; 0 mV, 6.8 6 0.9, n 5 25).
The change with voltage in the ratio of net charge:DA flux
indicated that not all DA-elicited current was stoichiometrically
coupled to DA translocation. This point has already been suggested for voltages above the leak conductance reversal potential
(approximately 218 mV), where the inhibitory action of DA on
the outward cation leak inflates the estimate of charges moving
inward. In contrast, the rise in the net charge:DA flux ratio with
hyperpolarization from 230 mV cannot be attributed to the same
mechanism: at more negative potentials, inhibition of a tonic
cationic leak current by DA would tend to diminish the net inward
current. Hence, if DA elicits an inward transport-associated current and simultaneously blocks a tonic inward leak, the observed
current will actually underestimate the magnitude of the
transport-associated charge movement and the net charge:DA
flux ratio. The elevation in the net charge:DA flux ratio attributable to hyperpolarization supports the existence of a second ionic
conductance that is associated with DA transport (see
Discussion).

Differentiation of pharmacological agents by I–V plots
To examine whether the hDAT-mediated currents elicited by DA
and cocaine are also elicited by other DA uptake inhibitors (or
releasers), a spectrum of pharmacological agents was assayed
using voltage-jump protocols with hDAT-expressing oocytes. Examination of drug-elicited steady-state currents revealed that the
ligands could be classified as either DA-like, cocaine-like, or
electrically inactive based on their I–V plots. The DA-like group
all displayed inverted U-shaped I–V curves with peaks at approximately 220 mV (Fig. 6 A, compare Fig. 4 A) and include the
psychomotor stimulants S(1)amphetamine and S(1)methamphetamine, the neurotoxin MPP1 (1-methyl-4-phenylpyridinium),
as well as (2)norepinephrine and the indirect sympathomimetic
agents p-tyramine, m-tyramine, b-phenethylamine, and (2)met-
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araminol. The catecholaminergic neurotoxin 6-hydroxydopamine
elicited no transport-associated current at 10 mM, and at a 30 mM
concentration, the transport-associated current (at 2120 mV) was
less than one-tenth the amplitude of that elicited by 10 mM
S(1)amphetamine in the same oocytes.
In contrast, a number of drugs manifested cocaine-like I–V
curves and appeared to reduce membrane conductance over the
entire range of membrane potentials. Their I–V plots (IControl 2
IDrug) reversed at approximately 220 mV and grew steeper at
positive potentials (Fig. 6 B, compare Fig. 2 B). Drugs falling in
this category include the stimulant /anorectic drugs methylphenidate, pemoline, amfonelic acid, phendimetrazine, aminorex, and
mazindol, as well as GBR12909, indatraline (Lu19-005), and the
cocaine analog RTI-55. Drugs that produced no detectable electrical responses in hDAT-expressing oocytes included the tyramine congeners with low potency for inhibiting [3H]DA uptake—
L-tyrosine (100 mM) and 3-methoxytyramine (30 mM)—and the
anti-parkinsonian drug amantadine (100 mM). At the concentrations tested, none of the drugs produced responses in waterinjected or uninjected oocytes.

Comparison of DA and cocaine actions on the steadystate leak currents

Figure 5. Voltage dependence of DA uptake velocity and of charge:DA
flux ratios determined in voltage-clamped uptake experiments. Oocytes
were voltage-clamped and superfused with DA or [3H]DA for 100 –300 sec
periods, after which the DA accumulated by each oocyte was quantitated
using HPLC-EC or scintillation counting (see Materials and Methods). A,
For each of six oocyte batches, uptake velocities at each potential were
normalized to that seen at 230 mV (dotted line). The normalized values
were pooled, and the mean values (6SEM) are plotted. The number of
oocyte batches and the total number of oocytes studied at each potential
are 1:3 at 110 mV, 5:25 at 0 mV, 6:28 at 230 mV, 6:31 at 260 mV, 6:28
at 290 mV, and 4:17 at 2120 mV. B, From current records available for
five of the six oocyte batches, net charge:DA flux ratios were calculated for
each oocyte from the time integral of currents elicited during periods of
DA perfusion and the corresponding measurements of accumulated DA.
Mean ratios (6SEM) for oocytes tested at each potential are graphed.
Means were compared with that determined at 230 mV (3.1 6 0.26) using
one-way ANOVA with a post hoc Dunnett’s multiple comparisons test,
and they differ with p , 0.01 (asterisk). The number of oocyte batches and
the total number of oocytes studied at each potential are 5:25 at 0 mV,
5:24 at 230 mV, 5:26 at 260 mV, 5:24 at 290 mV, and 3:10 at 2120 mV.
The dashed line at 2.0 represents the net charge:DA flux ratio predicted
for a fixed transport stoichiometry of 1 DA1/2 Na1/1 Cl2.

It is clear from the I–V plots of the hDAT ligands examined, that
like cocaine and DA at depolarized potentials, they too block a
tonic leak conductance (Fig. 6). Therefore, the question arises
whether substrates and nonsubstrate ligands inhibit an identical
leak conductance or whether they affect distinct conductances.
One criterion for determining whether two ligands affect the same
conductance is whether their I–V curves reverse at the same
potential. Because I–V plots of substrates do not cross the abscissa—a result of the drugs’ combined effects on the transportassociated and leak conductances—we reasoned that elimination
of the transport-associated component from the total DA-evoked
current might serve to isolate the membrane leak current that is
blocked by DA. To abolish the transport-associated currents,
buffer substitutions of K1 and Li1 were made for Na1, because
substrate translocation by hDAT shows strict dependence on Na1
ions. By examining the DA and cocaine I–V values in ionsubstituted buffers, their reversal potentials could be compared;
furthermore, the relative permeability of ions through the leak
conductance could be characterized by measuring the shifts in
reversal potential brought about by ion substitutions.
As expected, substitution of K1 for Na1 abolished the
transport-associated component of the DA I–V, altering its inverted U-shape to a more ohmic current, which does indeed
reverse and which now resembles the cocaine I–V. Figure 7A
illustrates that in 96 mM K1 (2 mM Na1) Ringer’s buffer, IControl
2 IDrug subtractions for both DA and cocaine generated I–V plots
that had comparable slope conductances over the entire voltage
range (contrast Fig. 3). The DA- and cocaine-inhibited conductances both reversed at 216 mV in 96K1 buffer—the same
potential at which the cocaine I–V reversed when assayed in
Na1-Ringer’s buffer during a previous trial on the same oocyte.
This reversal potential is not different from the mean reversal
potential (218.4 6 2.4 mV, mean 6 SEM) for cocaine I–V values
in Na1 Ringer’s buffer measured in 26 oocytes. When cocaine
reversal potentials were measured successively in individual oocytes using both Na1 Ringer’s and 48 mM K1/50 mM Na1 Ringer’s
buffers, these too showed that, despite a 24-fold increase in the
extracellular K1 concentration, the reversal potentials were not
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Figure 6. I–V plots readily distinguish two classes of pharmacological agents that act at hDAT. Nineteen hDAT ligands that were studied in voltage jump
protocols could be resolved into two groups, displaying either DA-like or cocaine-like voltage dependence of their subtractive currents. A, Substrates for
hDAT such as dopamine (F), p-tyramine (M), and amphetamine (É) elicit a conductance increase at potentials below 220 mV, and their subtractive
currents are plotted as IDrug 2 IControl. These and other compounds (listed below I–V plot) thought to be substrates for hDAT displayed a characteristic
inverted U-shaped I–V curve (see also Fig. 3A). B, In contrast, nontransported uptake inhibitors such as cocaine (F), GBR12909 (M), methylphenidate
(É), and other listed drugs all block an inward current at potentials below 220 mV and are plotted as IControl 2 IDrug. The reversal potential of the
conductance blocked by these drugs was approximately 220 mV and was independent of drug concentration (#30 mM). The I–V plots represent data
obtained from several different batches of oocytes, and each drug was tested in at least two hDAT oocytes. At the concentrations tested, none of the drugs
affected ionic conductances of control oocytes.

appreciably different: respectively, 214.3 6 5.7 mV and 215.4 6
3.2 mV (n 5 4 oocytes).
Substitution of Li1 for Na1 also eliminated substrateelicited transport-associated currents and revealed that the
leak currents blocked by substrates and nonsubstrate hDAT
inhibitors had indistinguishable reversal potentials. Successive
applications of DA and cocaine, both in 98 mM Li1 (0 Na1)
buffer, blocked conductances with reversal potentials of 0.0 6
3.1 mV and 20.8 6 3.2 mV, respectively (Fig. 7B, representative of 4 oocytes). Overall, the mean reversal potential for
cocaine in Li1 buffer was 4.2 6 3.1 mV (n 5 10 oocytes).
Comparable results were observed using Li1-substituted buffers with the substrates S(1)amphetamine, p-tyramine, and
b-phenethylamine, and the nonsubstrate blocker GBR12909
(data not shown). Furthermore, similar experiments have been
performed with DA and cocaine in buffer lacking both Na1 and
Cl2 (Li1 and MES substitutions, respectively), and the results
are qualitatively the same as those in Figure 7B (data from 3
experiments not shown). That Cl2 substitutions did not shift
the cocaine reversal potentials strongly suggests that Cl2 ions
are not carried by the hDAT leak conductance.
The Goldman–Hodgkin–Katz voltage equation was used to
characterize the ionic selectivity of the leak conductance from the
shifts in the cocaine reversal potential observed in ion-substituted
buffers. Assuming that the intracellular concentrations of Na1,
K1, and Li1 do not change appreciably, the relative permeabilities of these ions are 1, 0.96, and 2.4 for the hDAT leak conductance. That removal of all external Cl2 did not shift the cocaine
reversal potential suggests that the tonic hDAT leak conductance

is Cl2-impermeant, and yet it is fairly nonselective for alkali
cations. This ionic selectivity of the leak conductance differs
markedly from the comparatively strict dependence on Na1 and
Cl2 of the hDAT transport functions, i.e., substrate flux and
transport-associated currents.
The ionic selectivity of the leak conductance was explored
further with experiments in which reversal potentials were successively determined in individual oocytes from cocaine I–V plots
executed in Ringer’s buffer and in choline-substituted buffer.
Complete replacement of Na1 with choline caused leftward shifts
in the I–V curves. The mean reversal potentials shifted from
215.4 6 3.8 mV in Ringer’s to 248.4 6 4.0 mV in choline (n 5
7 oocytes), a value substantially more positive than the predicted
Nernst potential for K1 in oocytes (295 mV) (Dascal, 1987; Costa
et al., 1989). These results raise the possibility that choline or
some other ion may permeate the leak conductance aside from
Na1 and K1. Although removal of Ca21 or Mg21 from the
Ringer’s had no effect, manipulating the buffer between pH 6.5
and 8.5 strongly affected the cocaine reversal potentials, shifting
them approximately 238.5 6 3.5 mV per unit increase in pH (n 5
10 oocytes). These data suggest that protons may be carried by the
leak conductance or, alternatively, that pH can alter the ionic
selectivity of the leak. Because a 10-fold change in [H1]o had a
greater effect than an approximately 50-fold change in [Na1 1
K1]o and that [Na1 1 K1]o/[H1]o is $104, the Goldman–
Hodgkin–Katz voltage equation suggests that if protons do permeate through the leak conductance, their relative permeability is
more than four orders of magnitude greater than that of alkali
cations.
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and both ramp and steady-state currents evoked under voltageclamp conditions in oocytes injected with hDAT cRNA. Expression of the hDAT in oocytes gives rise to DA transport activity,
the pharmacological properties of which are consistent with those
displayed in heterologous mammalian cell lines transfected with
hDAT; the apparent affinity of DA uptake in oocytes, the inhibition constants for cocaine and S(1)amphetamine, as well as the
potencies of mazindol, GBR12935, and RTI-55, were within the
ranges determined previously in cell lines expressing hDAT (Giros et al., 1992; Pifl et al., 1993; Giros et al., 1994; Pristupa et al.,
1994; Eshleman et al., 1995). As would be expected for a member
of the Na1/Cl2-dependent neurotransmitter transporter family,
removal of either extracellular Na1 or Cl2 ions virtually abolished
the transport of [3H]DA into hDAT-expressing oocytes.

DA uptake and transport-associated current

Figure 7. Effects of Na1 substitution on leak conductance I–V relations. A,
Sequential application to a single oocyte of 3 mM cocaine in Na1 Ringer’s
buffer (f ), and then after a change to 96 mM K1 (2 mM Na1) Ringer’s buffer,
of 10 mM DA (Ç) and 3 mM cocaine (M). Subtractive currents (IControl 2
IDrug ) determined during voltage jump protocols represent the I–V of the leak
conductance, which is blocked by all three drug treatments. Cocaine I–V plots
display identical reversal potentials in the two buffers (216 mV in this cell).
In low Na1 buffer, the DA I–V displays the same reversal potential. Moreover, DA elicits no inward transport-associated current at negative potentials.
B, In 96 mM Li1 (2 mM Na1) Ringer’s buffer, voltage jumps during sequential
applications of 10 mM DA (É) and 10 mM cocaine (µ) reveal that both drugs
block a conductance with the same reversal potential (24 mV). Comparable
results were observed when Cl2 was replaced with MES in Li1 Ringer’s (not
shown). These data are representative of four repetitions.

Using two-electrode voltage-clamp techniques, we have found
that application of substrates to hDAT-expressing oocytes reliably
elicited voltage-dependent steady-state currents that were not
observed in control oocytes. When studied under conditions that
precluded substrate translocation, the electrophysiological actions
of substrates and nonsubstrate transport inhibitors revealed that
hDAT mediates a cationic leak conductance that is constitutive
and uncoupled from the uptake process. The two currents that
hDAT expression confers on oocytes are designated the
transport-associated and the leak currents.
Several lines of evidence suggest that the inward transportassociated current observed at hyperpolarized potentials after
application of DA (or other hDAT substrates) is closely linked to
substrate translocation by hDAT. The transport-associated current was caused by a conductance increase (Fig. 2C), consistent
with the coupled movement of a positively charged DA molecule
and Na1 ions. Numerous pharmacological attributes of the
transport-associated current were essentially identical to those of
[3H]DA uptake. The concentration dependence of [3H]DA uptake velocity and of DA-evoked transport-associated current amplitude were both well fit by rectangular hyperbolic functions with
similar kinetic constants (KT 5 1.7 mM and K0.5 5 1.9 –2.9 mM).
The set of pharmacological agents that evoked transportassociated currents includes compounds previously determined to
be substrates by biochemical assay (Fig. 6 A); conversely, nonsubstrate uptake blockers (e.g., cocaine and methylphenidate) were
unable to elicit transport-associated currents (Fig. 6 B). Furthermore, the apparent affinities of S(1)amphetamine were nearly
identical for inhibiting [3H]DA uptake (Ki 5 0.3 mM) and for
evoking transport currents (K0.5 5 0.5 mM), as would be expected
for a competitive inhibitor of DA uptake that is an alternative
transport substrate (Ross, 1976). Finally, treatments that prevented uptake of substrate, such as coincubation with pharmacologically appropriate concentrations of cocaine or replacement of
extracellular Na1 or Cl2, also abolished transport-associated currents evoked by DA (Figs. 3, 7).

Dependence of DA uptake on membrane potential
DISCUSSION
The Xenopus oocyte expression system has proven an exceedingly
useful method for investigating the function of cloned Na1coupled transport proteins, in part because both biochemical and
electrical indices of transport can be studied. To characterize the
electrogenic properties of a DAT cloned from human midbrain
RNA, we have measured substrate uptake, radioligand binding,

The close association of substrate-evoked voltage-dependent currents with substrate translocation strongly supports the assertion
that hDAT is an electrogenic transporter, a hypothesis developed
from studies of the apparent ionic coupling of rodent DATs
(Krueger, 1990; McElvain and Schenk, 1992; Kilty, 1993; Gu et al.,
1994). Our results provide direct evidence of the electrogenic
nature of hDAT in their demonstration that the velocity of DA
uptake increased with hyperpolarization (Fig. 5A). Several studies
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have demonstrated that the ability of striatal preparations to
accumulate [3H]DA uptake could be diminished by agents that
alter neuronal membrane potentials, such as ouabain, elevated
external K1 concentrations, veratridine, batrachotoxin, and metabolic inhibitors (Baldessarini and Vogt, 1971; Holz and Coyle,
1974; Liang and Rutledge, 1982; Krueger, 1990). One ambiguity
in these results, however, is that the effects of these agents on
membrane potential could not be separated from their effects on
the ionic gradients that drive substrate translocation.
hDAT-expressing oocytes, on the other hand, offered the opportunity to directly assess the influence of membrane potential
on DA uptake velocity, because the voltage could be manipulated
independently of ionic gradients, and the expression levels were
sufficient to allow the biochemical quantitation of DA accumulated by single cells during periods of voltage clamp. The increase
in uptake velocity observed with membrane hyperpolarization is
consistent with the expectation that the thermodynamic driving
force for an electrogenic transporter includes transmembrane
electrical potential, as well as chemical gradients for substrates
and cotransported ions. Furthermore, the data indicate that the
effect of membrane potential on DA uptake is mediated primarily
through alterations in the turnover rate (Vmax) of hDAT rather
than its apparent affinity for substrate, because DA concentrations
used in the clamped uptake experiments were near saturating. An
effect of voltage on turnover rate, but not on substrate affinity, is
also supported by the finding that the K0.5 of DA for eliciting
transport-associated currents was largely independent of membrane potential (Fig. 4 D). The voltage-dependent and ratelimiting step in the hDAT translocation reaction, therefore, is
likely to occur subsequent to substrate binding.
The clamped uptake experiments, apart from providing some
biophysical insight into hDAT translocation, also suggest a physiological context in which the voltage dependence of DA uptake
may help regulate intercellular signaling by dopaminergic neurons. Recent in vitro and in vivo studies have suggested that drugs
acting at D2-like autoreceptors modulate the velocity of DA
uptake (Meiergerd et al., 1993; Parsons et al., 1993; Cass and
Gerhardt, 1994), and the voltage dependence of hDAT function
demonstrated in our studies could provide the mechanism
through which autoreceptor activation influences DA reuptake. In
situ hybridization of rat DAT mRNA indicates that DAT is
expressed exclusively in dopaminergic neurons (Cerruti et al.,
1993; Lorang et al., 1994), and immunocytochemical studies demonstrate that terminal and somatodendritic zones of rat midbrain
DA neurons are rich in both DAT (Ciliax et al., 1995; Nirenberg
et al., 1996) and D2-like autoreceptors (Sesack et al., 1994; Yung
et al., 1995). Ample electrophysiological evidence shows that
activation of autoreceptors in dopaminergic cells in the substantia
nigra and ventral tegmental area causes the cells to hyperpolarize
through the G-protein-mediated opening of K1 channels (for
review, see Lacey, 1993; White, 1996). Our data predict that in
regions of dopaminergic neurons in which DAT and D2 receptors
are colocalized, hyperpolarization attributable to autoreceptor
activation by DA will increase the DAT turnover rate and thus
accelerate the clearance of extracellular DA. Faster removal of
extracellular DA complements the autoreceptor-mediated inhibition of DA release and may sharpen the temporal response of DA
signaling in these important cell groups. A second consequence
predicted from the colocalization of autoreceptors and DAT is
that the DA-activated K1 conductance would act to offset the
depolarizing action of the transport-associated current, and
thereby cancel the small, positive feedback effect that DA uptake
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might contribute toward promoting Ca21-dependent vesicular
DA release.

Two components of transport-associated currents
Despite the numerous common properties that appear to unite
transport-associated currents and substrate translocation in
hDAT-expressing oocytes, clamped uptake experiments suggested
that the transport-associated currents may be comprised of two
components, only one of which is stoichiometrically tied to substrate translocation. Concurrent measurement of DA-elicited currents and DA uptake in voltage-clamped oocytes provides strong
evidence that not all of the DA-elicited transport current arises
from stoichiometric coupling of 2 Na1 and 1 Cl2 ions per DA1
molecule, as predicted from biochemical studies of ionic activation of rat DAT uptake activity (Krueger, 1990; McElvain and
Schenk, 1992; Kilty, 1993; Gu et al., 1994) (but see Turner, 1985,
regarding putative transport stoichiometry). The mean net
charge:DA ratio displayed a minimum value of 3.1 in oocytes
clamped at 230 mV, a value that significantly exceeds the predicted ratio of 2 net charges per DA (CI99 2.4 –3.8; n 5 24; Fig.
5B). This divergence between charge and substrate flux is further
reflected in Figure 5B, in which the mean net charge:DA flux ratio
rises with hyperpolarization from 3.1 at 230 mV to 4.1 at 290 mV
and 6.6 at 2120 mV. Simply put, the DA transport-associated
currents are too large to be accounted for solely by a translocation
mechanism that operates with a fixed stoichiometry of 2 net
charges per DA molecule.
Two different mechanistic hypotheses might account for the
disparities between DA-elicited currents and uptake velocities.
One is that the DA transporter operates with variable coupling of
substrate and driving ions, and that hyperpolarization from 230
mV alters the ionic coupling such that more positive charges
accompany each translocated DA molecule. Alternatively, one
might posit that DA transport activates a distinct ionic conductance that is thermodynamically “uncoupled” from substrate
translocation. (Both explanations would be consistent with
transport-associated currents showing the same kinetics, ionic,
and pharmacological sensitivities as uptake activity.) Although
our data do not rule out either possibility, we favor the hypothesis
that substrate transport by hDAT can regulate an uncoupled ionic
conductance because several other electrogenic neurotransmitter
transporters have recently been shown to mediate ion fluxes that
are modulated by, but uncoupled from, substrate fluxes (Cammack et al., 1994; Mager et al., 1994; Fairman et al., 1995; Galli et
al., 1995; Wadiche et al., 1995; Cammack and Schwartz, 1996;
Eliasof and Jahr, 1996; Larsson et al., 1996; Risso et al., 1996) (for
review, see Sonders and Amara, 1996). In particular, it is interesting to compare the hDAT results with those obtained by Mager
and colleagues (1994), who studied oocytes expressing rat SERT.
They found that although hyperpolarization from 230 mV to 280
mV had virtually no effect on the velocity of serotonin uptake, it
markedly increased the transport-associated current elicited by
serotonin. In combination with the finding that the mean net
charge:serotonin flux ratio at 240 mV was 8.0 6 1.0, these results
suggest that a thermodynamically uncoupled component makes
an even greater contribution to the rSERT than to the hDAT
transport-associated current.
If a portion of the hDAT transport-associated current is indeed
stoichiometrically uncoupled from substrate movement, this
would suggest that hDAT mediates three discernible ionic conductances: the putative stoichiometrically coupled movement of
DA1/2 Na1/Cl2, a transport-activated uncoupled conductance,
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and the tonic leak conductance. The two uncoupled conductances
can be distinguished from each other because hDAT substrates
have opposing actions on these two uncoupled conductances. The
disparity is most obvious at hyperpolarized potentials, where the
inferred action of the DA-activated uncoupled conductance is to
increase the inward current, whereas the action of DA on the tonic
leak conductance is, in all likelihood, to block an inward current.

Characterization of the leak conductance
The action of DA on the tonic leak conductance at hyperpolarized
potentials is stated in a tentative manner, because it is ordinarily
masked by the transport-associated current under those ionic
conditions that permit substrate translocation. It was possible,
however, to isolate the action of DA on the tonic leak conductance from its action on transport-associated conductances by
replacing external Na1 in the superfusing Ringer’s buffer. When
K1, Li1, or choline was substituted for Na1, both specific [3H]DA
uptake into oocytes and the transport-associated inward current
elicited by DA were abolished (Fig. 7). Nevertheless, the ability of
drugs, including DA and cocaine, to block the leak conductance in
these buffers remained intact, and they did so at concentrations
essentially the same as those effective in normal Na1 Ringer’s. In
contrast to normal Na1 conditions, however, the I–V plots of DA
and cocaine were comparable across the entire voltage range;
furthermore, the I–V values reversed at the same potentials (Fig.
7), indicating that it is highly probable that both substrate and
nonsubstrate translocation inhibitors block an identical hDAT
leak conductance. Because ion substitution experiments revealed
that the leak conductance blockade by DA (and other substrates)
occurred at negative as well as positive potentials, it seems reasonable to infer that substrates also block the leak conductance at
negative potentials in Na1 Ringer’s despite the overwhelming
effect of the transport-associated currents they evoke.
The tonic leak conductance blocked by both DA and cocaine
also appears to be susceptible to inhibition by virtually all DAT
ligands tested regardless of their effect on the transport-associated
current. The inhibition can be seen in subtractive currents for all
drugs in the voltage range above 218 mV, where I–V curves for
substrates displayed a negative slope conductance (Fig. 6 A) and
those for translocation inhibitors displayed a positive slope conductance (Figs. 6 B, 7). The ability of substrates to block transporter leak currents is a relatively uncommon phenomenon
among Na1-dependent cotransporters. Although several members of this transporter superfamily display leak currents that can
be inhibited by nonsubstrate translocation blockers (Umbach et
al., 1990; Parent et al., 1992; Cammack et al., 1994; Mager et al.,
1994; Chen et al., 1995; Galli et al., 1995; Vandenberg et al.,
1995), only hDAT, rSERT (Mager et al., 1994), and perhaps a rat
GABA transporter (GAT1) (Cammack and Schwartz, 1996) appear to have leak conductances that are also inhibited by
substrates.
The leak conductances of hDAT and rSERT also share a rather
uncommon ionic selectivity. Analysis of the shifts in the cocaine
reversal potential attributable to ion substitution for Na1 indicate
that Li1 and K1 are, respectively, 2.4-fold and 0.96-fold as permeant as Na1 through the hDAT leak conductance. These values
are reasonably close to the estimates of Mager and colleagues
(1994), who report that the magnitude of the rSERT leak current
is increased threefold by substitution of Li1 for Na1, but reduced
by 27% by K1 substitution. We found no evidence suggesting that
Cl2 anions are carried in the leak conductance; however, the
robust shifts in the cocaine reversal potential observed with alter-
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ations in the buffer pH suggested that protons may also permeate
the hDAT leak conductance—a phenomenon currently being
investigated. It is somewhat surprising that, in contrast to the
stringent Na1 and Cl2 requirements for substrate translocation,
the tonic leak conductance of hDAT readily carries Li1 and K1,
and perhaps H1, ions. Like hDAT and rSERT, uncoupled conductances mediated by GAT1 are also supported by several alkali
cations (Cammack and Schwartz, 1993, 1996; Cammack et al.,
1994; Mager et al., 1996). In contrast, the leak “modes” of many
other transporters display comparable ionic selectivities to their
transport modes (for review, see Maloney, 1994; Sonders and
Amara, 1996). Thus, it is an open question for hDAT and other
members of this family whether a single permeation pathway
mediates both the net vectorial movement of substrate/cosubstrate ions and also the bidirectional flux of leak ions or whether
the transporters contain separate pathways that have markedly
different ionic selectivities.
Similarly, it is not currently known whether the site at which
substrates bind to block the leak conductance is in the permeation
pathway or outside of it. Our ion substitution results indicate,
however, that the binding of cosubstrate ions is not a prerequisite
for substrate binding and leak blockade, because DA readily
blocks the leak conductance in the complete absence of external
Na1 and Cl2. Should this DA binding site be located within the
substrate permeation pathway, the ion substitution experiments
would suggest that the strict dependence of the hDAT transport
function on Na1 and Cl2 is not attributable to the ion-dependent
binding of substrates, as has been suggested for GAT1 (Mager et
al., 1996). Although hDAT and GAT1 belong to the same family
of Na1/Cl2-dependent transporters, they can also be mechanistically distinguished by the finding that the K0.5 for DA-elicited
transport-associated currents is independent of voltage for hDAT
(Fig. 4 D), whereas the K0.5 for GABA-elicited current at GAT1
rises with hyperpolarization (Mager et al., 1993). It is possible that
the voltage dependence of the GABA K0.5 may arise from the
initial voltage-dependent binding of Na1, which was recently
described by Mager and coworkers (1996).

hDAT currents as a pharmacological tool: implications
for DAT-mediated DA release
The demonstration that the transport-associated and leak currents are intrinsic to hDAT function helps to highlight the possibility that the psychomotor stimulants, a class of drugs with broad
societal relevance, may influence the electrical properties of neurons directly as well as indirectly through the regulation of extracellular DA levels. For instance, the observation that hDAT leak
conductance can be inhibited by the same pharmacological agents
and concentrations as those affecting DA translocation suggests
that drugs such as cocaine, methylphenidate, pemoline, and
mazindol modulate ionic flux as well as substrate uptake into
dopaminergic cells in vivo. If protons are indeed carried by the
hDAT leak conductance, our data suggest that the selectivity and
voltage dependence of the leak is comparable to that of voltageactivated proton-selective conductances (DeCoursey and Cherny,
1994). One proposed function of these proton conductances is to
enable the rapid alkalinization of the cytoplasm under conditions
of heightened metabolic activity without further energy expenditure (for review, see Lukacs et al., 1993). If the hDAT leak serves
a similar purpose, psychostimulants may directly influence the
physiology of dopaminergic neurons by interfering with intracellular pH homeostasis.
Apart from the physiological consequences of the ionic currents
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of hDAT, the transport-associated and leak currents provide new
tools with which to elucidate hDAT pharmacology and the mechanisms of action of psychomotor stimulants. Using the criterion of
whether drugs elicited transport-associated currents, it was easy to
discriminate hDAT substrates from nonsubstrate translocation
inhibitors (Fig. 6). Our categorization accords well with and
extends the current understanding of how drugs act on hDAT.
Because both substrate and nonsubstrate ligands inhibit uptake of
radiolabeled substrates by DAT, differentiation of the two classes
of drugs has relied on two types of biochemical assays. By one
approach, striatal preparations or transfected cells are used to
measure the sequestration of putative substrates that have been
radiolabeled or are detectable by other methods (e.g., electrochemistry, chromatography, spectrophotometry, or a combination). The second approach assesses the ability of putative substrates to promote the efflux of an authentic preloaded substrate,
presumably through a mechanism akin to carrier-mediated facilitated diffusion (Stein, 1986). Nearly all of the compounds identified as substrates by electrophysiological assay have been shown
previously to promote Ca21-independent efflux of [3H]DA with a
pharmacological profile appropriate to DAT (Heikkila et al.,
1975; Raiteri et al., 1977, 1979; Fischer and Cho, 1979; Liang and
Rutledge, 1982; Bonnet et al., 1984; Keller and Da Prada, 1985;
Chang and Ramirez, 1986; Parker and Cubeddu, 1986; Rollema et
al., 1986; Sirinathsinghji et al., 1988; Eshleman et al., 1995; Pifl et
al., 1995; Wall et al., 1995). Metaraminol has not been studied
previously as a promoter of [3H]DA efflux; however, it is an
indirect sympathomimetic agent that promotes Ca21-independent
“release” of norepinephrine stores (Langeloh et al., 1987), underscoring the similarity among substrates for DAT and NET (Kilty,
1993; Buck and Amara, 1994). Conversely, cocaine and other
drugs we have identified electrophysiologically as nonsubstrate
translocation inhibitors have typically been reported to inhibit
both releaser-elicited and spontaneous [3H]DA efflux at low
concentrations.
Although assays of uptake and efflux have formed the basis of
the contemporary classification of hDAT substrates and nonsubstrate inhibitors, they have not provided altogether unambiguous
results, because the endpoints measured in such assays do not
measure the activity of DAT alone but can also be influenced by
agents that modify DA synthesis, degradation, and vesicular sequestration, as well as those that alter membrane potential and
spontaneous release processes. Indeed, although it is well accepted that amphetamine, methamphetamine, and several
b-phenethylamine congeners are excellent releasers of DA, the
direct evidence indicating that these compounds can be taken up
by DAT is scarce (Zaczek et al., 1991) compared with the data
available for their less lipophilic, hydroxylated analogs (Steinberg
and Smith, 1970; Baldessarini and Vogt, 1971; Dorris and Shore,
1971; Fischer and Cho, 1979). It has been proposed that the
amphetamine-like releasing agents passively diffuse into the cell
and increase DA efflux through their actions at an intracellular
target (for review, see Seiden et al., 1993); by causing depletion of
vesicular DA through a weak base mechanism, amphetamines
elevate levels of cytosolic DA and promote its extrusion by DAT
(Sulzer and Rayport, 1990; Sulzer et al., 1995). However, this
model does not implicate any direct action of these releasers on
DAT. In light of the several lines of evidence supporting the
hypothesis that the transport-associated current is an indicator of
ongoing hDAT translocation activity, the finding that S(1)amphetamine, S(1)methamphetamine, and b-phenethylamine all
elicit transport-associated currents strongly suggests that they

interact directly with hDAT and are substrates. To our knowledge, this is the first data, apart from biochemical release experiments, to indicate that S(1)methamphetamine is indeed a DAT
substrate. These data support the idea that these drugs promote
DA efflux through a sort of exchange mechanism involving hDAT,
in addition to any intracellular actions they may have.

Conclusion
Data have been presented that indicate that hDAT mediates both
a transport-associated current and a constitutive leak current in
Xenopus oocytes, and that these currents can be distinguished
from each other by the criteria of ionic dependence and selectivity, voltage dependence, and the opposing actions substrates have
on them. Furthermore, our evidence suggests that the transportassociated current itself is complex and may arise from two ionic
conductances, both of which are activated by DA under conditions
that permit substrate translocation (or a single transport conductance that operates with variable coupling). In contrast, the tonic
leak conductance is inhibited by hDAT substrates and nontranslocated uptake blockers alike. All three putative conductances
appear to be sensitive to individual hDAT ligands in the same
concentration range, and therefore, all may be of potential relevance to the actions of hDAT agents. We do not know whether
the three conductances are all intrinsic to a single transporter
molecule, to hDAT oligomers, or to distinct subpopulations of
modified hDAT molecules, or whether some ionic conductance
attributed to hDAT is indirectly mediated through an extrinsic
protein (Sonders and Amara, 1996).
Although our results predict that neuronal membrane potential
will directly modulate hDAT uptake activity, at this stage it is not
known whether hDAT-mediated currents contribute significantly
to the electrical properties of dopaminergic neurons in vivo.
Whole-cell currents attributable to neurotransmitter uptake have
been demonstrated in a variety of neuronal and glial cells (for
review, see Lester et al., 1994; Sonders and Amara, 1996). Estimation of the turnover rate for hDAT in oocytes, 0.47 DA
molecules /sec at 218C, indicates that the transporter is relatively
slow and must reside at comparatively high density in terminal
areas for it to effectively modulate extracellular DA concentrations, as has been suggested from work with rat striatal preparations (Boja et al., 1994). Accordingly, it is conceivable that the
density of DATs may be high enough that even the small currents
associated with hDAT expression in oocytes could affect the
membrane potential in regions of dopaminergic neurons with high
input resistance. Future experiments should reveal whether DAT
influences the electrical signaling properties of dopaminergic neurons in a capacity beyond its function of regulating DA recycling.
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